TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

Standard BioTools Inc.


Financial Advisor, January 2024

Standard BioTools Inc.
Exchange of all Outstanding Series B Convertible Preferred Stock for Common Stock

Standard BioTools Inc. (Nasdaq: LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.

More Like This

Jan 2024
$350 Million

2.50% Senior Convertible Notes

Lead Manager

View Details >
May 2022
$82 Million

Series C Convertible Preferred

Exclusive Placement Agent

View Details >
Nov 2021
$690 Million

1.50% Senior Convertible Notes


View Details >